Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Asset Resilience Ratio
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has an Asset Resilience Ratio of 12.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Nanjing King-friend Biochemical Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.25 Billion | 12.14% |
| Total Liquid Assets | CN¥1.25 Billion | 12.14% |
Asset Resilience Insights
- Moderate Liquidity: Nanjing King-friend Biochemical Pharmaceutical Co Ltd has 12.14% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Cronos Group Inc
NASDAQ:CRON |
Drug Manufacturers - Specialty & Generic | 3.34% |
|
Evoke Pharma Inc
NASDAQ:EVOK |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Medical Marijuana I
PINK:MJNA |
Drug Manufacturers - Specialty & Generic | 0.03% |
|
James E Wagner Cultivation Corp
PINK:JWCAF |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
CanaQuest Medical Corp
PINK:CANQF |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Innovativ Media Group Inc
PINK:DMAN |
Drug Manufacturers - Specialty & Generic | 53.58% |
Annual Asset Resilience Ratio for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.10% | CN¥1.06 Billion | CN¥9.51 Billion | +3.94pp |
| 2023-12-31 | 7.16% | CN¥681.99 Million | CN¥9.52 Billion | +7.15pp |
| 2022-12-31 | 0.01% | CN¥1.30 Million | CN¥10.01 Billion | -3.15pp |
| 2021-12-31 | 3.16% | CN¥259.80 Million | CN¥8.22 Billion | -7.79pp |
| 2020-12-31 | 10.96% | CN¥845.79 Million | CN¥7.72 Billion | +9.84pp |
| 2019-12-31 | 1.12% | CN¥56.64 Million | CN¥5.08 Billion | -18.18pp |
| 2017-12-31 | 19.30% | CN¥520.00 Million | CN¥2.69 Billion | +5.42pp |
| 2015-12-31 | 13.87% | CN¥180.00 Million | CN¥1.30 Billion | +13.77pp |
| 2014-12-31 | 0.11% | CN¥1.64 Million | CN¥1.54 Billion | -- |